Pharmafile Logo

Wegovy

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Wegovy in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Wegovy.

30

Global Revenue Ranking

8

2030 Global forecast Ranking

Recent articles on PMLiVE featuring Wegovy

- PMLiVE
Novo Nordisk’s Wegovy approved by FDA as oral medication for weight management

Those taking the 25mg pill lost a similar amount of weight as those using injectable Wegovy 2.4mg

- PMLiVE
Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

- PMLiVE
Novo Nordisk agrees to lower certain drug prices in the US

The company’s semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

- PMLiVE
Novo Nordisk reports sales growth in 2025 as R&D pipeline advances

Growth driven by increased sales in diabetes and obesity markets

- PMLiVE
Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m

The deal gives Lilly exclusive global rights to incretin products based on Camurus’ technology

- PMLiVE
Eli Lilly’s Zepbound shows superiority in head-to-head weight loss study

Patients treated with Lilly’s drug achieved an average weight reduction of 20.2%

- PMLiVE
Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease

Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year

- PMLiVE
Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease

The progressive condition affects approximately 40% of type 2 diabetes patients

- PMLiVE
Novo shares promising results for high-dose semaglutide in late-stage obesity study

The experimental dose is also being evaluated in adults with obesity and type 2 diabetes

- PMLiVE
Novo Nordisk’s GLP-1 drug semaglutide shows promise in fatty liver disease MASH

The company expects to file for regulatory approvals of the drug in this indication next year

- PMLiVE
Novo Nordisk receives CHMP recommendation for Wegovy cardiovascular label update

The weight management drug was found to significantly reduce the risk of major adverse cardiovascular events

- PMLiVE
Novo Nordisk’s semaglutide approved by MHRA to prevent cardiovascular event risk

Approximately 7.6 million people are living with heart and circulatory diseases in the UK

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links